Sandoz

ZIEXTENZO

Manufacturer:

Sandoz

Ziextenzo HCPCS:

Q5120

HCPCS Code Descriptor:

Injection, pegfilgrastim-bmez (ziextenzo), biosimilar, 0.5 mg

Category:

Q Code

Ziextenzo NDCs:

61314-0866-01

Primary Type:

Oncology Biosimilar Colony Stimulating Factor

Generic/Specialty Status:

Single-Source

Package Type:

Syringe

Route of Administration:

Subcutaneous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Ziextenzo:

ZIEXTENZO is an Oncology Biosimilar Colony Stimulating Factor drug manufactured by Sandoz and administered via the Subcutaneous route of administration. The Q Code: Q5120 is aligned to the drug ZIEXTENZO.

Ziextenzo (pegfilgrastim) is used to prevent the lack of certain white blood cells (neutrophils) in the body by aiding in the production of these white blood cells. This medication is manufactured by Sandoz and is biosimilar to the drug Neulasta (J2506). Ziextenzo was aligned to the HCPCS code Q5120 July 2020. Patient assistance programs for this medication can be found through the Sandoz One Source program.

ACCESS PRICING AND MORE BY REGISTERING

Q5120 Added Date:

July 1, 2020

Q5120 Effective Date:

April 1, 2023

Q5120 Termination Date:

HCPCS Active

Ziextenzo billing and coding information can be found through Sandoz at the link below:
Ziextenzo patient assistance information can be found through Sandoz at the URL: https://ziextenzo.com/
ZIEXTENZO prescribing information can be found at the link below:
Information regarding ZIEXTENZO’s side effects can be found at MedlinePlus